Open-Angle Glaucoma

The most popular glaucoma articles on Healio/OSN in September include a current look at MIGS, the use of a nonvalved aqueous drainage implant and an update on a phase 2 trial.

Interim results from a phase 3b clinical trial in Europe showed Roclanda was non-inferior to Ganfort, according to a press release.

The FDA has approved Aerie Pharmaceuticals’ sterile fill facility in Athlone, Ireland, for the production of Rhopressa for commercial distribution in the U.S., according to a press release.

Patients with glaucoma treated with the Omni surgical system in the GEMINI study experienced a statistically significant reduction in both IOP and IOP-lowering medications.

Sight Sciences has initiated patient enrollment in the ORION clinical study of the Omni surgical system in pseudophakic eyes, according to a press release.

Combined treatment of cataract surgery with iStent or iStent inject trabecular bypass stent showed benefits to the ocular surface and overall improvement in ocular surface disease.

The FDA has accepted the premarket approval application for Santen Pharmaceutical’s DE-128 microshunt for review, according to a press release.

Nicox has enrolled the first 12 patients in a phase 3 clinical trial evaluating NCX 470, a novel second-generation nitric oxide-donating bimatoprost analog.

A progression report provided comparable predictions for the risk of fast visual field progression in patients with open-angle glaucoma, according to a retrospective multicenter study published in the Journal of Glaucoma.

Researchers observed a link between office-hour IOP and peak nocturnal IOP in a group of patients with primary open angle glaucoma and ocular hypertension, according to a study published in the American Journal of Ophthalmology.